Loading patent…
AssigneesThe United States of America, as represented by the Secretary, Department of Health and, Human Services
InventorsPatrick Hwu, Gang Wang, Warren Leonard, Rosanne Spolski, Katsutoshi Ozaki
Estimating the term…
A method of treating and/or preventing cancer in a subject, preferably mammalian, more preferably human, by administering in an effective amount IL-21 polypeptide, polynucleotide, vector comprising an IL-21 nucleic acid sequence encoding an IL-21 polypeptide, variants, and fragments thereof, thereby acting as an anti-cancer agent by reducing, ameliorating, and/or eliminating the cancer; and a method of treating and/or preventing cancer in a subject by co-administering the IL-21 polypeptide, polynucleotide, IL-21 vector, variant, and fragments thereof, with an immunotherapeutic and/or chemotherapeutic agent for the treatment and/or prevention of cancer in a subject.
A method of treating a cancer in a mammal, comprising administering to a mammal afflicted with cancer an IL-21 polypeptide, variant, or fragment of either of the foregoing in an amount effective to treat the cancer in the mammal.
-7. (canceled)
-10. (canceled)
A method of treating an immune-related disease in a mammal, comprising administering to a mammal afflicted with an immune-related disease an IL-21 polypeptide, variant, or fragment of either of the foregoing, in an amount effective to treat the immune-related disease in the mammal.
A method of preventing a cancer in a mammal, comprising administering to a mammal an IL-21 polypeptide, variant, or fragment of either of the foregoing in an amount effective to prevent the cancer in the mammal.
-24. (canceled)
-27. (canceled)
-38. (canceled)
A method for inducing apoptosis of a natural killer (NK) cell comprising contacting the NK cell with an amount of an IL-21 polypeptide, variant, or fragment of either of the foregoing, effective to induce apoptosis of the natural killer cell.
A method of activating NK cell cytolytic activity, comprising contacting the NK cell with an amount of an IL-21 polypeptide, variant, or fragment of either of the foregoing, effective to activate NK cell cytolytic activity.
Dependencies are inferred from the claim text.